Episode Details

The FDA has granted De Novo classification to Spectral MD's DeepView AI System, a software that predicts burn wound healing. Maya and Sam unpack the device's indications, the strict special controls required, and what this new regulatory category means for future medtech developers.

Key points

• The FDA established a new Class II generic device type for software-aided adjunctive diagnostic devices used in skin wound assessment.
• DeepView AI detects deep burn tissue and highlights areas unlikely to heal within 21 days with conservative treatment.
• The device is strictly an adjunctive aid and its segmentation contour is not for definitive delineation of surgical excision borders.
• Developers must prove their AI improves diagnostic characterization compared to unaided users across diverse clinical risk factors.
• Special controls require extensive testing, including human factors, electromagnetic compatibility, and photobiological safety of light-emitting components.

Source: DeepView AI® System - U.S. Food and Drug Administration, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/will-ai-redefine-burn-triage-unpacking-the-fda-s-deepview-ai-de-novo-o-cc00c9